Drug intelligence / Profile preview

nonivamide

Development stage
Unknown
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Topical, Oral, Intranasal
01

Overview

Nonivamide, also known as pelargonic acid vanillylamide or PAVA, is a synthetic analog of capsaicin and a capsaicinoid. This small molecule is commonly manufactured synthetically and is utilized in the pharmaceutical industry for its analgesic and anti-inflammatory properties. It is primarily administered topically in creams, ointments, and patches for conditions such as muscle and joint pain, including acute low back pain. Nonivamide's main mechanism involves activating the transient receptor potential vanilloid 1 (TRPV1) receptor, leading to a sensation of heat followed by desensitization and pain relief. Additionally, it has been investigated for its role in preventing dietary-induced body fat gain and its anti-inflammatory effects, which may involve inhibiting the NF-κB/NLRP3 pathway.

Brand names
FinalgonZostrix
Other names
pelargonic acid vanillylamidenonylic vanillylamideN-[4-hydroxy-3-methoxy-benzyl]nonanamideN-vanillylnonamidenonylic acid vanillyl amidevanillyl pelargonic amidepelargonyl vanillyl amidepseudocapsaicinsynthetic capsaicin
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on nonivamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nonivamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call